Back to search
Blasts More Than 5 Percent of Bone Marrow Nucleated Cells
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Blasts More Than 5 Percent of Bone Marrow Nucleated Cells trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Blasts More Than 5 Percent of Bone Marrow Nucleated Cells trials you may qualify forThis phase I trial studies best dose and side effects of liposome-encapsulated daunorubicin-cytarabine (CPX-351) and how well it works in treating patients with…
This phase II trial studies the side effects and how well Vyxeos works in treating patients with intermediate and high-risk acute myeloid leukemia who have fail…
This phase II trial studies how well ruxolitinib works in treating patients with hypereosinophilic syndrome or primary eosinophilic disorders.